Clinical trials: Psoriasis Chronic
Psoriasis (PsO), Psoriasis Arthritis
Molecular Inflammation Board at the Center for Personalized Medicine
Molecular Inflammation Board at the Center for Personalized Medicine
- Conditions
- Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Spondylarthropathies
- Trial name
- MEB@ZPM (NCT07132333)
- Testing
- Biologic Agent
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Tuebingen
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Effect of Chronic Inflammation on Myocardial Perfusion and Function
Background: Heart failure (HF) is a public health burden. Studies have shown a link between inflammation, myocardial dysfunction, and HF.
- Trial name
- NCT04870827
- Testing
- 13N Amonia
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Plaque Psoriasis
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
- Trial name
- PsOsim (NCT02489227)
- Testing
- CHS-1420, Adalimumab
- Where
- 99 sites in United States, Bulgaria and 14 more
- Volunteers
- 545 people
- Sponsor
- Coherus Oncology, Inc.
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Chronic Stable Plaque Psoriasis
Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis
This is a 12-week, open-label, pilot trial evaluating the efficacy and safety of the combination of Clobex® spray with excimer laser therapy as the initial treatment of generalized plaque psoriasis, followed by maintenance…
- Trial name
- NCT01012713
- Testing
- Clobex Spray, Vectical Ointment, Excimer Laser
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Healthy Volunteers, Mild to Moderate Psoriasis
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of…
- Trial name
- NCT05965089
- Testing
- AX-202
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Arxx Therapeutics
Psoriasis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
- Trial name
- NCT01519089
- Testing
- CP-690,550, CP-690, 550
- Where
- 16 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling
The purpose of this study is to collect skin biopsies and non-invasive microneedle device samples from participants with mild chronic plaque psoriasis vulgaris to use for transcriptomics profiling for further investigation.
- Trial name
- NCT03795402
- Testing
- Microneedle Device
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Safety and Efficacy of Secukinumab in Mild Psoriasis
Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities.
- Trial name
- NCT03131570
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- James G. Krueger, MD, PhD
Psoriasis
Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life
Objective of the study is to create and validate Chronic Quality of Life (CQOL) index that explores habits, career paths and other life choices psoriasis patients make as a result of coping with their disease that may not be…
- Trial name
- NCT00823914
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Massachusetts General Hospital
Psoriasis
Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
Psoriasis, the most prevalent autoimmune disease in the U.S., manifests with plaque type psoriasis vulgaris with lesions localized to the scalp, postauricular region, face, diaper area, elbows, and knees.
- Trial name
- NCT03848806
- Testing
- HAT1, Calcipotriol
- Volunteers
- 174 people
- Sponsor
- Haus Bioceuticals
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE RADIANT (NCT03536884)
- Testing
- Bimekizumab, Secukinumab
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 743 people
- Sponsor
- UCB Biopharma SRL
Psoriasis, Alopecia Areata
Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases
This project aims to develop and evaluate an online intervention to prevent and/or reduce self-stigma in German patients with visible chronic skin diseases.
- Conditions
- Psoriasis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- DEVISE (NCT06324695)
- Testing
- HautKompass
- Where
- 12 sites in Germany
- Volunteers
- 298 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chronic Inflammatory Disease
Chronic Inflammatory Rheumatism: Management of Comorbidities in Ambulatory Medicine
Identification of factors limiting compliance with the recommendations established during the evaluation of the SCORIC population by the rheumatology department of the CHU Grenoble Alpes
- Trial name
- SCORIC-A (NCT05613712)
- Testing
- Patients, Referring physician
- Where
- France
- Volunteers
- 229 people
- Sponsor
- University Hospital, Grenoble
Chronic Plaque-type Psoriasis
Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis
The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with…
- Trial name
- NCT07844772
- Testing
- IL-17 Inhibitor Therapy, Conventional Systemic Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul Training and Research Hospital
Chronic Plaque Psoriasis
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult…
- Trial name
- DERMIS-1 (NCT04211363)
- Testing
- Roflumilast 0.3% cream, Vehicle Cream
- Where
- 40 sites in United States, Canada
- Volunteers
- 439 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- Opportuniti (NCT04785326)
- Testing
- DMB-3115, Stelara
- Where
- 2 sites in United States
- Volunteers
- 598 people
- Sponsor
- Dong-A ST Co., Ltd.
Moderate to Severe Chronic Plaque Psoriasis
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for…
- Trial name
- NCT05388916
- Testing
- Cosentyx
- Where
- 7 sites in China
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals